Wall Street brokerages expect Aratana Therapeutics Inc (NASDAQ:PETX) to report sales of $5.70 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aratana Therapeutics’ earnings, with the lowest sales estimate coming in at $5.20 million and the highest estimate coming in at $6.20 million. Aratana Therapeutics posted sales of $6.16 million during the same quarter last year, which would indicate a negative year over year growth rate of 7.5%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that Aratana Therapeutics will report full-year sales of $26.80 million for the current fiscal year, with estimates ranging from $20.50 million to $38.10 million. For the next financial year, analysts anticipate that the firm will report sales of $47.57 million per share, with estimates ranging from $40.10 million to $52.60 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $4.72 million.

A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating and set a $5.50 price target for the company in a research note on Tuesday, August 7th. ValuEngine cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. Stifel Nicolaus decreased their price target on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a report on Monday, May 7th. Finally, BidaskClub raised Aratana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 10th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $8.25.

Aratana Therapeutics stock traded up $0.14 during midday trading on Wednesday, reaching $5.32. The company’s stock had a trading volume of 177,694 shares, compared to its average volume of 314,868. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.44 and a current ratio of 3.02. Aratana Therapeutics has a 52-week low of $3.67 and a 52-week high of $7.28. The stock has a market cap of $255.52 million, a PE ratio of -5.48 and a beta of 2.78.

In other news, COO Brent Standridge sold 10,000 shares of the stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $4.56, for a total value of $45,600.00. Following the transaction, the chief operating officer now directly owns 99,967 shares of the company’s stock, valued at $455,849.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Steven St sold 11,513 shares of the firm’s stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $4.33, for a total value of $49,851.29. Following the sale, the insider now directly owns 649,233 shares in the company, valued at $2,811,178.89. The disclosure for this sale can be found here. Insiders sold 39,187 shares of company stock worth $186,472 over the last three months. Corporate insiders own 5.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its holdings in Aratana Therapeutics by 1.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,010,448 shares of the biopharmaceutical company’s stock worth $4,456,000 after acquiring an additional 10,404 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Aratana Therapeutics by 23.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 17,300 shares during the period. Goldman Sachs Group Inc. grew its holdings in Aratana Therapeutics by 35.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 17,677 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Aratana Therapeutics during the fourth quarter worth about $110,000. Finally, Geode Capital Management LLC grew its holdings in Aratana Therapeutics by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 313,626 shares of the biopharmaceutical company’s stock worth $1,649,000 after acquiring an additional 21,654 shares during the period. 66.90% of the stock is currently owned by hedge funds and other institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: Asset Allocation

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.